KUALA LUMPUR, Malaysia (AP) — Malaysian Prime Minister Anwar Ibrahim on Tuesday won a reprieve in a civil suit accusing him of sexual misconduct, after a court approved his bid to temporarily suspend the trial due to start next week.
The suit was filed in 2021 by his former research assistant, Muhammed Yusoff Rawther. Yusoff, 32, alleged that Anwar sexually harassed him in 2018 — before Anwar became premier, in November 2022. Anwar, 77, denies any wrongdoing and accuses Yusoff of fabricating the charge to ruin his political career.
The case gained attention after Anwar sought immunity from prosecution, sparking criticism from the opposition and others. The High Court dismissed his application last week, saying everyone is equal before the law. Anwar has turned to the nation’s top court, which will hear his case on July 21.
The Court of Appeal on Tuesday approved Anwar’s bid for a temporary stay to the trial that was due to start June 16, pending next month's hearing in the Federal Court.
Anwar wants the Federal Court to rule on several legal questions including whether a sitting prime minister has immunity from lawsuits stemming from alleged private events before his appointment. His lawyers claimed the legal action could impair his ability to govern and risk destabilizing the government.
The case could undermine Anwar, who heads a unity government comprised of rival factions. He has denied seeking personal immunity or trying to escape legal scrutiny.
“It concerns the integrity of our constitutional system and the need to ensure that high public office is protected from litigation that may be strategically timed, politically motivated or institutionally disruptive,” he wrote on Facebook last week.
Anwar, a former reformist opposition leader, was previously jailed twice for sodomy. He has said the charges against him were manufactured by the government to thwart his opposition party. Anwar was pardoned by the king in 2018, just months before the alleged sexual assault on Yusoff.
Yusoff is currently in detention and on trial after police found drugs and fake pistols in his car last September. He has said he was framed by those in power. The court will decide this Thursday whether he needs to enter his defense, or acquit him.
Malaysian Prime Minister Anwar Ibrahim delivers his speech during the 22nd Shangri-La Dialogue summit in Singapore, Saturday, May 31, 2025. (AP Photo/Anupam Nath)
CUYAHOGA FALLS, Ohio--(BUSINESS WIRE)--Jan 13, 2026--
As medical device manufacturers face mounting pressures to reduce environmental risk, improve traceability, and accelerate product development, Americhem is preparing to highlight a suite of new technologies that reflect these industry shifts at Pharmapack (Paris) and MD&M West (Anaheim) in early 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112893294/en/
The company, known for its healthcare-focused polymer compounds and masterbatches, will showcase five key technologies, each designed to respond to the technical and regulatory complexities facing modern medtech—particularly in areas like connected care, self-administered delivery, and robotic-assisted interventions. Among the engineered solutions:
Americhem is actively engaging with OEM partners to co-develop and validate them for next-generation device applications. The company reports continued double-digit growth in its healthcare segment, supported by its ISO 13485-certified facilities in the U.S. and Denmark and upcoming expansion into China in 2026.
Americhem will also participate in the SPE Minitec Conference held during MD&M West, joining technical discussions on materials innovation for evolving care models.
“There’s a clear shift happening—material choices are now deeply tied to sustainability goals, regulatory scrutiny, and device functionality,” said Matt Miklos, Vice President of Corporate Strategy and M&A at Americhem. “What we’re bringing to these shows is not a catalog—it’s a pipeline of engineered solutions designed to be customized, scaled, and validated in partnership with OEMs who are navigating that complexity every day.”
Americhem’s approach emphasizes long-term material consistency, global compliance, and early design collaboration—factors increasingly prioritized by engineering and R&D teams charged with building the next wave of medical devices.
For technical inquiries or to request early access to sample materials, visit www.americhem.com/industries/healthcare/.
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world. Visit www.Americhem.com for more information.
Engineered for medical nonwovens, Americhem’s PFAS-free nDryve™ additive delivers fluorine-free fluid repellency to surgical gowns, hygiene drapes, and barrier fabrics—addressing OEM demand for safer, sustainable performance in single-use healthcare textiles.
Americhem’s laser-marking ready thermoplastics enable permanent, high-contrast part identification directly on molded medical components—ideal for cleanroom environments where labels or inks are not viable. Designed for compliance and traceability, these materials support regulatory and workflow demands in modern device manufacturing.
